about
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate CancerRegimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)Placental Passage and Disposition of Drugs: A Physiology-based ApproachAn Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C VirusHIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and EtravirineEvaluating Once Daily Etravirine in Treatment-Naive Adults With HIV InfectionChanges in Body Composition Under Ustekinumab in PsABone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine RegimenEfficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's DiseaseRelative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy SubjectsStudy of Acute Uncomplicated Seasonal Influenza A in Adult Subjects"InDACtion" vs "3+7" Induction in AMLEvaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in AfricaStudy of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety DisorderSchizophrenia, Antipsychotic Treatment and the Risk for Diabetes MellitusRisperidone Augmentation for PTSDEvaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.Risperidone and Suicidality in Major Depressive DisorderRisperdal Consta for Bipolar DisorderA Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia NervosaA Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate CancerA Study of Letrazuril in the Treatment of AIDS-Related DiarrheaA Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDSStudy Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsSingle Cell Genomics of Psoriatic SkinA Phase I Study of Mebendazole for the Treatment of Pediatric GliomasCyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsStudy of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone LevelsAssessing Progression to Type-2 Diabetes (APT-2D): A Prospective Cohort Study Expanded From BRITE-SPOT (Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes)International Registry for Patients With Castleman DiseaseDoes CERC-501 Attenuate Stress-precipitated Smoking Lapse?A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected,Antidepressant Trial With P2X7 Antagonist JNJ-54175446Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult ParticipantsAn Explorative Psoriasis Biomarker StudyA Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European CountriesDaratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
P767
Q57010196-47DAAC4D-5439-4513-A4B7-E615C4CBA56DQ63583679-D945FEE5-3897-4C99-9046-22A7116CBDF8Q73258577-5C43ED94-F20A-4185-B0F5-912FCE0307C1Q86375184-6F6FD7E6-DC76-4B1E-B250-DB541A0BA159Q87176914-51255495-8DE2-47E8-9D38-BA0393D19987Q88437373-DE2BF496-99FF-42CB-9290-FD67B0B14A8AQ90063732-8A3E593D-EE24-4300-8B8F-97F4350DDEC6
P108
Q64188643-DD2FB02E-54BE-48F6-8843-9B424A983D96Q64363802-D8C900DE-7664-4AFE-8135-0F0FAD498AD0Q64394252-279B9375-AA67-45F6-9AB0-774B1AC3A430Q64397100-5CC0C508-7D4D-40D2-AEFC-73A145B6C617Q64640502-4DBE4DDA-4C76-4B6E-88C5-C5FAF812F9C8Q64679441-02813736-1EF1-423C-8A35-717ABBDB36A8Q64695658-A4AF7B04-55D1-4F4B-96C4-603183D82511Q64793713-5AC13B59-B0DF-4198-8638-17BE4A652786Q65344986-7A9E9BCD-3421-49CF-90BB-FB568223468EQ65346181-CDB6523B-A94B-4879-8C1F-890899B5A8C9Q65347385-2CE306FC-21A2-48AB-A132-E171D6ECD1EDQ65349182-83C4C354-A556-424C-B9F1-F624E5AEC6A2Q65354000-92E94749-337A-47F4-B3E3-F8857B32A3D0Q65362157-EFFCEB8D-0451-4F1F-9C4F-C4AD09B1CA1AQ65539051-701D6E17-A823-4E91-845E-ECF243310CFBQ65543732-15889689-8334-4562-A51E-42DA07B8C530Q65544911-1003EC91-2689-46D0-90E8-23662BA83DEAQ65545051-1EC4303B-7C14-4646-8928-814775D1BBD3Q66026460-6680A4D1-4BE9-4BAA-80CA-E1D19F5D6464Q66026471-253B46F0-444E-401A-8DC9-10BDE34BE4C7Q66028485-12EDA916-6630-437A-9707-74A766A5F036Q66034200-1DB8FC78-17ED-4FC9-B57D-4B4020DC328BQ66040694-2DE398AF-4700-4360-B1DE-1DD6321B1821Q66040739-C669D232-6073-494F-8C5A-4642D2AD8EB4Q66078566-111B0E12-297B-4191-954B-58290ADFADBCQ66081169-9416B77A-CD9D-47B4-8381-3611F5906460Q66343784-BE0D0DC2-2463-4BAC-9E39-292DB714BD08Q66392844-D9FA11C1-C6F2-485C-BA65-88DF9FAB6B5FQ66393561-85344316-1B09-4203-8706-0DA2BCCCB9A0Q66396050-8CB2E2DA-3F34-4903-A87E-AD41B4368BEFQ66399229-C4F3D723-F2FD-47DF-9CF4-16F2A0D05872Q66399459-942C46C5-AEF1-4F2B-B686-4CFD7BDF27BBQ66401375-3D489E27-72DA-443D-8101-189786004A8DQ67134435-FA00352D-DD29-40A5-B6D1-D51F5A3A4AF6Q74276880-A00BF8BA-11AD-4CDA-B38E-92AD47171DC7Q86245787-733B09BF-0863-4A8D-8A91-BCD2C4322E9FQ93214766-1680B5D6-98E8-4335-935E-081AC4BA5D22Q94982456-D238F9BF-B43C-428E-AB82-DC3DADB3DA97Q95172341-B2DFD0CE-36E0-43F7-9195-C3A94FF0C96BQ95799568-B88BFDE0-0939-47EC-A3A9-182994658C19
P767
description
bedrijf uit Verenigde Staten van Amerika
@nl
business enterprise in United States of America
@en
name
Janssen Pharmaceuticals
@en
type
label
Janssen Pharmaceuticals
@en
altLabel
Janssen Pharmaceuticals, Inc.
@en
prefLabel
Janssen Pharmaceuticals
@en
P1278
P3153
P1278
549300KW7Q8FTDG2UO48